Lilly’s Taltz hits goals in PhIII ankylosing spondylitis trial

Regulatory submissions for Lilly’s Taltz in ankylosing spondylitis (AS) are on the cards for later this year after the drug hit primary and secondary targets in a late-stage trial.Original Article